Booklet Provides Guidance on Appointing or Being a Health Care Proxy

Publication
Article
OncologyONCOLOGY Vol 12 No 12
Volume 12
Issue 12

Choice In Dying (Washington, DC) recently released a new booklet entitled, “Healthcare Agents: Appointing and Being One,” intended to serve as a reference when appointing a health care agent (proxy) or acting as one.

Choice In Dying (Washington, DC) recently released a new booklet entitled, “Healthcare Agents: Appointing and Being One,” intended to serve as a reference when appointing a health care agent (proxy) or acting as one. Providing answers to common questions and highlighting difficult topics everyone should consider, the new booklet helps individuals select agents who will be successful advocates and also helps reduce agents’ uncertainty over which decisions best reflect the patients’ wishes.

Among other important issues, the booklet urges people to talk with family members and agents about medical treatment decisions and personal values as a way to ensure that their dignity and quality of life will be respected. People should not assume that their closest relatives would automatically want to be agents or will know their wishes, the booklet warns.

The thoughtful appointment of a health care agent is one of the best ways to ensure that end-of-life medical care decisions are heard, understood, and honored. “Instead of seeing end-of-life decisions as a blank canvas on which others will paint, put the paint brush in your own hands. Appoint a proxy and paint a picture of the life you want to live up to the last minute. Protect your choices and at the same time protect your family from the emotional anguish and conflict of not knowing your wishes. That is the best gift you can give them,” said Dr. Karen Kaplan, executive director of Choice In Dying.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.